Keung Wendy, Cheung Yiu-Fai
Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Pokfulam, Hong Kong.
Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
Front Pharmacol. 2021 Apr 19;12:650039. doi: 10.3389/fphar.2021.650039. eCollection 2021.
Anticancer chemotherapies have been shown to produce severe side effects, with cardiotoxicity from anthracycline being the most notable. Identifying risk factors for anticancer therapy-induced cardiotoxicity in cancer patients as well as understanding its underlying mechanism is essential to improving clinical outcomes of chemotherapy treatment regimens. Moreover, cardioprotective agents against anticancer therapy-induced cardiotoxicity are scarce. Human induced pluripotent stem cell technology offers an attractive platform for validation of potential single nucleotide polymorphism with increased risk for cardiotoxicity. Successful validation of risk factors and mechanism of cardiotoxicity would aid the development of such platform for novel drug discovery and facilitate the practice of personalized medicine.
抗癌化疗已被证明会产生严重的副作用，其中蒽环类药物引起的心脏毒性最为显著。识别癌症患者中抗癌治疗引起心脏毒性的风险因素并了解其潜在机制，对于改善化疗治疗方案的临床结果至关重要。此外，针对抗癌治疗引起心脏毒性的心脏保护剂稀缺。人类诱导多能干细胞技术为验证具有增加心脏毒性风险的潜在单核苷酸多态性提供了一个有吸引力的平台。成功验证心脏毒性的风险因素和机制将有助于开发此类用于新药发现的平台，并促进个性化医疗的实践。
